Organogenesis Holdings Inc
ORGO3.060USD
-2.280-42.70%
Close 05/09, 16:00（ET）Quotes delayed by 15 min
388.17MMarket Cap
LossP/E TTM
More Details of Organogenesis Holdings Inc Company
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
Company Info
Company codeORGO
Company nameOrganogenesis Holdings Inc
IPO dateDec 02, 2016
Founded at2018
CEOMr. Gary S. Gillheeney, Sr.
Number of employees869
Security typeOrdinary Share
Fiscal year-endDec 02
Address85 Dan Rd
CityCANTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02021-2810
Phone17815750775
Websitehttps://investors.organogenesis.com
Company codeORGO
IPO dateDec 02, 2016
Founded at2018
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Glenn H. Nussdorf
Mr. Glenn H. Nussdorf
Director
Director
11.91M
--
Mr. Alan A. Ades
Mr. Alan A. Ades
Director
Director
11.19M
--
Mr. Patrick Bilbo
Mr. Patrick Bilbo
Chief Operating Officer
Chief Operating Officer
487.05K
+40.33%
Mr. Brian Grow
Mr. Brian Grow
Chief Commercial Officer
Chief Commercial Officer
253.50K
+144.18%
Mrs. Lori Freedman, J.D.
Mrs. Lori Freedman, J.D.
Chief Administrative and Legal Officer
Chief Administrative and Legal Officer
208.85K
+148.85%
Mr. Antonio S. Montecalvo
Mr. Antonio S. Montecalvo
Vice President - Health Policy
Vice President - Health Policy
188.20K
+17.78%
Mr. Arthur S. Leibowitz, CPA
Mr. Arthur S. Leibowitz, CPA
Lead Independent Director
Lead Independent Director
186.17K
+36.29%
Ms. Prathyusha Duraibabu, CPA
Ms. Prathyusha Duraibabu, CPA
Independent Director
Independent Director
143.42K
+52.83%
Mr. Jon L. Giacomin
Mr. Jon L. Giacomin
Independent Director
Independent Director
139.41K
+55.19%
Dr. Gilberto Quintero, Ph.D.
Dr. Gilberto Quintero, Ph.D.
Independent Director
Independent Director
139.22K
+55.30%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Glenn H. Nussdorf
Mr. Glenn H. Nussdorf
Director
Director
11.91M
--
Mr. Alan A. Ades
Mr. Alan A. Ades
Director
Director
11.19M
--
Mr. Patrick Bilbo
Mr. Patrick Bilbo
Chief Operating Officer
Chief Operating Officer
487.05K
+40.33%
Mr. Brian Grow
Mr. Brian Grow
Chief Commercial Officer
Chief Commercial Officer
253.50K
+144.18%
Mrs. Lori Freedman, J.D.
Mrs. Lori Freedman, J.D.
Chief Administrative and Legal Officer
Chief Administrative and Legal Officer
208.85K
+148.85%
Mr. Antonio S. Montecalvo
Mr. Antonio S. Montecalvo
Vice President - Health Policy
Vice President - Health Policy
188.20K
+17.78%
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
By BusinessUSD
Name
Revenue
Proportion
Advanced Wound Care
453.64M
94.11%
Surgical & Sports Medicine
28.40M
5.89%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Advanced Wound Care
453.64M
94.11%
Surgical & Sports Medicine
28.40M
5.89%
Shareholder
Update time: Mon, May 5
Update time: Mon, May 5
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Soleus Capital Management, L.P.
9.84%
Nussdorf (Glenn H)
9.39%
Morgan Stanley & Co. LLC
9.26%
Ades (Alan A)
8.82%
Erani (Dennis)
7.92%
Other
54.77%
Shareholder Statistics
Shareholder
Proportion
Soleus Capital Management, L.P.
9.84%
Nussdorf (Glenn H)
9.39%
Morgan Stanley & Co. LLC
9.26%
Ades (Alan A)
8.82%
Erani (Dennis)
7.92%
Other
54.77%
Type
Shareholder
Proportion
Individual Investor
32.67%
Investment Advisor/Hedge Fund
15.21%
Corporation
14.12%
Hedge Fund
12.51%
Research Firm
10.79%
Investment Advisor
9.42%
Sovereign Wealth Fund
0.38%
Pension Fund
0.17%
Bank and Trust
0.07%
Other
4.66%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
311
121.05M
95.42%
-4.67M
2024Q4
344
121.01M
95.72%
-4.65M
2024Q3
354
109.09M
82.30%
-7.23M
2024Q2
369
107.79M
81.32%
-6.45M
2024Q1
374
102.47M
77.65%
-12.90M
2023Q4
378
102.14M
77.80%
-10.89M
2023Q3
390
113.75M
86.92%
-11.36M
2023Q2
400
112.98M
86.34%
-14.25M
2023Q1
400
117.68M
90.49%
-17.51M
2022Q4
400
121.78M
93.79%
-42.01M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Soleus Capital Management, L.P.
12.48M
9.84%
+645.00K
+5.45%
Dec 31, 2024
Nussdorf (Glenn H)
11.91M
9.39%
--
--
Jan 09, 2025
Morgan Stanley & Co. LLC
11.75M
9.26%
-139.57K
-1.17%
Dec 31, 2024
Ades (Alan A)
11.19M
8.82%
-1.00
-0.00%
Jan 09, 2025
Erani (Dennis)
10.04M
7.92%
--
--
Jan 09, 2025
Organo PFG LLC
8.28M
6.53%
--
--
Jan 09, 2025
RED Holdings, L.L.C.
6.78M
5.35%
--
--
Jan 09, 2025
BlackRock Institutional Trust Company, N.A.
4.75M
3.74%
-23.82K
-0.50%
Dec 31, 2024
The Vanguard Group, Inc.
3.59M
2.83%
-82.64K
-2.25%
Dec 31, 2024
Acadian Asset Management LLC
3.08M
2.43%
+65.66K
+2.17%
Dec 31, 2024
View more
Related ETFs
Update time: Tue, May 6
Update time: Tue, May 6
Name
Proportion
WisdomTree US SmallCap Fund
0.12%
iShares Micro-Cap ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
Franklin US Small Cap Multifactor Index ETF
0.04%
DFA Dimensional US Small Cap Value ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
Fidelity Enhanced Small Cap ETF
0.03%
SPDR S&P Biotech ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Invesco FTSE RAFI US 1500 Small-Mid ETF
0.02%
View more
WisdomTree US SmallCap Fund
Proportion0.12%
iShares Micro-Cap ETF
Proportion0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.06%
Franklin US Small Cap Multifactor Index ETF
Proportion0.04%
DFA Dimensional US Small Cap Value ETF
Proportion0.03%
Avantis US Small Cap Equity ETF
Proportion0.03%
Fidelity Enhanced Small Cap ETF
Proportion0.03%
SPDR S&P Biotech ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.02%
Invesco FTSE RAFI US 1500 Small-Mid ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data